Preface to the Series, Preface, Contributors, 1 Recombinant Antibodies: Construction and Production, 2 Bispecific Antibodies, 3 Targeted Cytotoxicity: Antibody-Drug and Antibody-Toxin Conjugates, 4 Selective Drug Delivery Using Targeted Enzymes for Prodrug Activation, 5 Immunoscintigraphy and Radioimmunotherapy, 6 Clinical Studies in Oncology, 7 Clinical Studies in Acute and Chronic Inflammation, 8 Marrow Purging and Stem Cell Preparation, Index
Siegfried Matzku is head of the Department of Gene Expression and Biotechnology within Preclinical Research of Merck KGaA and he has an affiliation with the University of Karlsruhe, Faculty of Biology and Geology. He is the author of over I 00 research articles and articles in books. His research interests stem from his longstanding work at the German Cancer Research Center, Heidelberg, and he pursues those in the pharmaceutical industry: tumor biology (adhesion molecules), tumor diagnosis (immunoscintigraphy) and tumor therapy (monoclonal antibodies and recombinant antibody constructs).Rolf A. Stabel is senior physician at the Division of Oncology, Department of Medicine and head of the Laboratory of Oncology. University Hospital Ziirich Switzerland. He is associate professor of Medical Oncology at the University of Zurich, Switzerland. He has authored over 130 research articles, the majority on the development of new therapeutic approaches to lung cancer and on the treatment of malignant lymphomas. in particular high dose chemotherapy. His main research interests developed during his training in medical oncology at the Dana Farber Cancer Institute, Boston, Massachusetts.